Generation of safe and efficient, off-the-shelf, chimeric antigen receptor (CAR)-engineered T cells for broad application

Kenneth C Anderson

Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies Pathology

Martha Lassiter

Duke University Nursing Oncology Training Exchange with Tata Memorial Hospital

Non-Hodgkin lymphoma Multiple myeloma and immunoproliferative diseases Leukaemia Hodgkin lymphoma Breast

Catriona HM Jamieson

(PQC2) Niche-responsive RNA editing by ADAR1 in dormant multiple myeloma initiating cell maintenance

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies Pathology

Antoinette Stroup

PATTERNS OF CARE/QUALITY OF CARE STUDY : DIAGNOSIS YEAR 2014

Multiple myeloma and immunoproliferative diseases Leukaemia Colorectum

Jetze J Tepe

Characterization of Non-Competitive Proteasome Binding

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies Pathology

Nathaniel Rothman

DDT, PCBs, and Other Persistent Organohalide Chemicals in the JANUS Cohort

Trachea, bronchus and lung Thyroid Testis Prostate Pancreas Ovary Non-Hodgkin lymphoma Multiple myeloma and immunoproliferative diseases Lip, oral cavity Leukaemia

Hematology and hematologic malignancies Pathology

Anneclaire J De Roos

Occupational Pesticide Use and Risk of Lymphoid Cancers

Non-Hodgkin lymphoma Multiple myeloma and immunoproliferative diseases Leukaemia

Qing Lan

A Hospital-based Case-control Study of Lymphoma in Asia (AsiaLymph)

Non-Hodgkin lymphoma Multiple myeloma and immunoproliferative diseases Leukaemia Hodgkin lymphoma

Hematology and hematologic malignancies

Daniel M Sullivan

CRM1 INHIBITORS SENSITIZE MULTIPLE MYELOMA CELLS TO TOPOISOMERASE II AND PROTEASOME INHIBITORS

Multiple myeloma and immunoproliferative diseases